BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposiu...
February 04 2019 - 8:22AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today that Chaim
Lebovits, CEO, will provide a corporate presentation at the BIO CEO
& Investor Conference on February 11, 2019 in New York City.
The BIO CEO & Investor Conference is one of the largest
investor conferences focused on established and emerging publicly
traded and select private biotech companies.
Ralph Kern MD, MHSc, Chief Operating Officer and
Chief Medical Officer will present a poster at the Extracellular
Vesicles in Diagnostics & Therapeutics Symposium on February
19, 2019 in New York City. Presented by The New York Academy of
Sciences (NYAS), The Extracellular Vesicles in Diagnostics &
Therapeutics Symposium will review the most recent advances in
Research & Development and the increasing impact of EVs on
Diagnostics and Drug Development for Cancer, Neurodegenerative
Disease and Cardiovascular Disease.
|
2019 BIO CEO & Investor Conference
Details: |
Date:
|
Monday, February 11,
2019 |
Presenter: |
Chaim Lebovits,
CEO |
Time: |
10:15 AM Eastern
Standard Time |
Location: |
New York Marriott
Marquis Hotel in Times Square |
Webcast:
|
https://goo.gl/nggSJK |
|
Extracellular Vesicles in Diagnostics & Therapeutics
Symposium Details: |
Date: |
Tuesday, February 19,
2019 |
Presenter: |
Ralph Kern MD, MHSc,
COO & CMO |
Poster: |
Development of MSC-NTF
(NurOwn®) Derived Exosomes for the Treatment of Neurodegenerative
Diseases |
Time: |
4:15 PM Eastern
Standard Time |
Location: |
The New York Academy of
Sciences, 7 World Trade Center, Floor 40 |
|
|
Investor MeetingsBrainStorm senior management
will be hosting institutional investor meetings at the 2019 BIO CEO
& Investor Conference. Please use the Investor contact
information provided below to schedule a meeting.
About NurOwn® Technology PlatformNurOwn®
technology platform (autologous MSC-NTF cells) represents a
promising investigational therapeutic approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm is
currently conducting a Phase 3 pivotal trial (NCT03280056) of
autologous MSC-NTF cells for the treatment of amyotrophic lateral
sclerosis (ALS). BrainStorm recently received U.S. FDA acceptance
to initiate a Phase 2 open-label multicenter trial (NCT03799718) in
progressive Multiple Sclerosis (MS) and plans to start enrollment
in early 2019.
About BrainStorm Cell Therapeutics,
Inc. BrainStorm Cell Therapeutics Inc. is a
leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® technology platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement. Autologous MSC-NTF cells have received Orphan
Drug status designation from the U.S. Food and Drug Administration
(U.S. FDA) and the European Medicines Agency (EMA) in ALS.
BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS
(NCT03280056), investigating repeat-administration of autologous
MSC-NTF cells at six sites in the U.S., supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a filing for
U.S. FDA approval of autologous MSC-NTF cells in ALS. For more
information, visit BrainStorm's website at
www.brainstorm-cell.com.
Safe-Harbor Statements
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Media:Joseph PetrozielloBrainStorm Cell TherapeuticsPhone:
+1.215.485.6797Email: JP@brainstorm-cell.com
Investors:Marcy Beth NanusSolebury TroutPhone:
+1.646.378.2927Email: MNanus@troutgroup.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Sep 2023 to Sep 2024